• 1
    Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 24362441.
  • 2
    Tan J, Lok AS. Update on viral hepatitis: 2006. Curr Opin Gastroenterol 2007; 23: 263267.
  • 3
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 4
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975978.
  • 5
    Hadziyannis SJ, Cheinquer H, Morgan T. Peginterferon alfa-2a (40KD) in combination with ribavirin: efficacy and safety results from a phase III randomized, double-blind multicenter study examining the effect of duration of treatment and RBV dose (Abstract). J Hepatol 2002; 36: 3
  • 6
    Bowden DS, Berzsenyi MD. Chronic hepatitis C virus infection: genotyping and its clinical role. Future Microbiol 2006; 1: 103112.
  • 7
    Darling JM, Fried MW. Optimizing treatment regimens in hepatitis C. Clin Liver Dis 2006; 10: 835850.
  • 8
    Timm J, Roggendorf M. Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J Gastroenterol 2007; 13: 48084817.
  • 9
    Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 2007; 20: 2338.
  • 10
    Neumann-Haefelin C, Spangenberg HC, Blum HE, Thimme R. Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection. World J Gastroenterol 2007; 13: 48394847.
  • 11
    Chen TY, Hsieh YS, Wu TT, Yang SF, Wu CJ, Tsay GJ, et al. Impact of serum levels and gene polymorphism of cytokines on chronic hepatitis C infection. Transl Res 2007; 150: 116121.
  • 12
    Bondini S, Younossi ZM. Non-alcoholic fatty liver disease and hepatitis C infection. Minerva Gastroenterol Dietol 2006; 52: 135143.
  • 13
    Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, Su GL, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007; 13: 11001108.
  • 14
    Mulhall BP, Younossi Z. Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. J Clin Gastroenterol 2005; 39: S23S27.
  • 15
    Nagaki M, Imose M, Naiki T, Kimura K, Hayashi H, Shimizu M, et al.; the GH Study Group. Prospective study on early virologic response to treatment with interferon alpha-2b plus ribavirin in patients with chronic hepatitis C genotype 1b. Hepatol Res 2005; 33: 285291.
  • 16
    Ferenci P, Fried MW, Shiffman M, Smith CI, Marinos G, Gonçales FL Jr, et al. Predicting sustained virologic response in chronic hepatitis C patients treated with peginterferon alfa-2a and ribavirin. J Hepatol 2005; 43: 425443.
  • 17
    Davis GL. Predictability of SVR: pooled results peg-IFN α-2b + RBV [Abstract]. HEPATOLOGY 2002; 36( Suppl): S145S151.
  • 18
    Dantzler TE, Lawitz EJ. Treatment of chronic hepatitis C in nonresponders to previous therapy. Curr Gastroenterol Rep 2003; 5: 7885.
  • 19
    Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. HEPATOLOGY 2006; 43: 954960.
  • 20
    Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J Antimicrob Chemother 2004; 53: 1518.
  • 21
    Asselah T, Bieche I, Narguet S, Sabbagh A, Laurendeau I, Ripault MP, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008; 57: 516524.
  • 22
    Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. HEPATOLOGY 2007; 46: 15481563.
  • 23
    Berzsenyi MD, Roberts SK, Beard MR. Genomics of hepatitis B and C infections: diagnostic and therapeutic applications of microarray profiling. Antivir Ther 2006; 11: 541552.
  • 24
    Baranova A, Schlauch K, Gowder S, Collantes R, Chandhoke V, Younossi ZM. Microarray technology in the study of obesity and non-alcoholic fatty liver disease. Liver Int 2005; 25: 10911096.
  • 25
    Baranova A, Liotta L, Petricoin E, Younossi ZM. The role of genomics and proteomics: technologies in studying non-alcoholic fatty liver disease. Clin Liver Dis 2007; 11: 209220.
  • 26
    Dallas PB, Gottardo NG, Firth MJ, Beesley AH, Hoffmann K, Terry PA, et al. Gene expression levels assessed by oligonucleotide microarray analysis and quantitative real-time RT-PCR – how well do they correlate? BMC Genomics 2005; 6: 59.
  • 27
    Wang Y, Barbacioru C, Hyland F, Xiao W, Hunkapiller KL, Blake J, et al. Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays. BMC Genomics 2006; 7: 59.
  • 28
    Ilyin SE, Horowitz D, Belkowski SM, Xin H, Eckardt AJ, Darrow AL, et al. Integrated expressional analysis: application to the drug discovery process. Methods 2005; 37: 280288.
  • 29
    Garcia EP, Dowding LA, Stanton LW, Slepnev VI. Scalable transcriptional analysis routine–multiplexed quantitative real-time polymerase chain reaction platform for gene expression analysis and molecular diagnostics. J Mol Diagn 2005; 7: 444454.
  • 30
    Higuchi R, Fockler C, Dollinger G, Watson R. Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. Biotechnology (N Y) 1993; 11: 10261030.
  • 31
    Rogge L, Bianchi E, Biffi M, Bono E, Chang SY, Alexander H, et al. Transcript imaging of the development of human T helper cells using oligonucleotide arrays. Nat Genet 2000; 25: 96101.
  • 32
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402408.
  • 33
    Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001; 98: 51165121.
  • 34
    Rajendra A, Wong JB. Economics of chronic hepatitis B and hepatitis C. J Hepatol 2007; 47: 608617.
  • 35
    Lang L. HCV findings presented at EASL: long-term follow-up and the criteria of a cure. Gastroenterology 2007; 132: 22822283.
  • 36
    Tateno M, Honda M, Kawamura T, Honda H, Kaneko S. Expression profiling of peripheral-blood mononuclear cells from patients with chronic hepatitis C undergoing interferon therapy. J Infect Dis 2007; 195: 255267.
  • 37
    Ji X, Cheung R, Cooper S, Li Q, Greenberg HB, He XS. Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. HEPATOLOGY 2003; 37: 610621.
  • 38
    Kaplan DE, Sugimoto K, Ikeda F, Stadanlick J, Valiga M, Shetty K, et al. T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C. HEPATOLOGY 2005; 41: 13651375.
  • 39
    Neumann-Haefelin C, Blum HE, Chisari FV, Thimme R. T cell response in hepatitis C virus infection. J Clin Virol 2005; 32: 7585.
  • 40
    Nelson DR. The immunopathogenesis of hepatitis C virus infection. Clin Liver Dis 2001; 5: 931953.
  • 41
    Bigger CB, Guerra B, Brasky KM, Hubbard G, Beard MR, Luxon BA, et al. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 2007; 81: 33913401.
  • 42
    Taylor MW, Tsukahara T, Brodsky L, Schaley J, Sanda C, Stephens MJ, et al. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol 2004; 78: 1377913792.
  • 43
    Kohavi R. A study of cross-validation and bootstrap for accuracy estimation and model selection. In: Proceedings of the Fourteenth International Joint Conference on Artificial Intelligence; August 20-25, 1995; Montreal, Canada. Vol. 2: 11371143.
  • 44
    Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008; 105: 70347039.